A5142/PH III/LOPINAVIR/RITONAVIR+EFAVIR FOR INITIAL THERAPY OF HIV-1 INFECTION

A5142/PH III/洛匹那韦/利托那韦 EFAVIR 用于 HIV-1 感染的初始治疗

• 批准号: 7378380
• 负责人: ROY M. GULICK
• 金额: $ 16.75万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378380
• 关键词: A5142; PH; III; LOPINAVIR; RITONAVIR+EFAVIR

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this study is to compare the time to virologic failure pairwise between the three treatment groups: lopinavir/ritonavir plus efavirenz, lopinavir/ritonavir plus d4T extended release (or zidovudine) plus 3TC, and efavirenz plus d4T extended release (or zidovudine) plus 3TC, and to compare the time to regimen completion pairwise between the three treatment groups: lopinavir/ritonavir plus efavirenz, lopinavir/ritonavir plus d4T extended release (or zidovudine) plus 3TC, and efavirenz plus d4T extended release (or zidovudine) plus 3TC. Regimen completion will be defined as either virologic failure or toxicity-related discontinuation of any component of the initial randomized treatment regimen.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本研究的主要目的是比较三个治疗组（洛匹那韦/利托那韦+依法韦仑、洛匹那韦/利托那韦+d4 T缓释剂）之间至病毒学失败的时间（或齐多夫定）加3 TC和依法韦仑加d4 T缓释（或齐多夫定）加3 TC，并比较三个治疗组之间的方案完成时间：洛匹那韦/利托那韦加依法韦仑、洛匹那韦/利托那韦加d4 T缓释（或齐多夫定）加3 TC和依法韦仑加d4 T缓释（或齐多夫定）加3 TC。方案完成将定义为病毒学失败或初始随机化治疗方案任何组分的毒性相关停药。